IMEXHS Wins Mexico Tender for Aquila+ Deployment

Smallcaps reports that IMEXHS has won a public tender in Mexico to deploy its Aquila+ AI-integrated radiology platform via distributor partner GOBA, adding US$384,000 in new annual recurring revenue (ARR) and a US$50,000 one-time implementation fee. Smallcaps states the contract covers deployment across 20 hospitals and clinics, with roll-out commencing recently and completion expected by end-June 2026, and full ARR run-rate anticipated from September 2026. Smallcaps also reports the deployment will include five proprietary AI workflow agents embedded in Aquila+ and two Gleamer diagnostic algorithms, ChestView and Fracture Detection.

Per the Smallcaps report, the MX tender integrates vendor-supplied AI workflow agents and third-party algorithms within the Aquila+ platform; the article lists ChestView and Fracture Detection from Gleamer as the specific diagnostic algorithms included. The Smallcaps coverage frames the deal as a full platform deployment across multiple site types (hospitals and clinics) rather than a pilot, with an associated implementation fee and ARR uplift.

IMEXHS reported FY25 results in an ASX filing summarised by Open Briefing showing FY25 revenue of US$29.0m, ARR of US$34.8m (up 16% vs prior year), Underlying EBITDA of US$1.6m, cash of US$3.3m, and debt of US$0.5m at 31 December 2025. Open Briefing also noted operational scale with 8.2 million studies processed across 564 installed sites in 18 countries and platform uptime at 99.8% for the year.

Editorial analysis: Companies selling enterprise medical-imaging platforms commonly secure growth through channel-led public tenders because such deals bundle software subscription revenue with implementation fees and multi-site scale. For practitioners, tender-driven deployments raise integration and deployment complexity compared with single-site pilots, particularly when third-party AI algorithms are embedded across multiple clinical workflows.

The reported inclusion of vendor-proprietary AI workflow agents together with certified diagnostic algorithms reflects a broader pattern where imaging platform vendors combine orchestration, workflow automation, and third-party inference to accelerate clinical adoption. Observers following the sector will watch for evidence that channel partners like GOBA can deliver consistent deployment timelines and validation across varied hospital environments.

• •Completion timing and revenue recognition: confirm roll-out milestones and when the reported US$384,000 ARR is reflected in run-rate recognition.
• •Integration and validation: look for technical documentation or clinical validation notes on how the embedded algorithms (Gleamer ChestView, Fracture Detection) are integrated into Aquila+ workflows and any local regulatory clearances cited for Mexico.
• •Partner traction: monitor further partner-led enterprise wins to gauge whether channel-led growth scales beyond single-country tenders.

Editorial analysis: The FY25 financials summarised in the ASX filing show a profitable swing at the underlying EBITDA line and an expanding ARR base, which industry observers typically interpret as improving unit economics for recurring-software vendors. That pattern can increase investor comfort, but it depends on execution consistency across implementations and channel partners.

Notes on sources: tender details and technical points are taken from the Smallcaps article; FY25 financials and operational metrics are taken from IMEXHS FY25 ASX disclosures as summarised by Open Briefing.